nach oben

Drugs & Aging

Erschienen in:

01.01.2012 | Commentary

Long-Standing Statin Therapy and the Risk of New-Onset Diabetes in the Elderly

Collateral Damage Caused by Preventive Medicine?

verfasst von: Dr Luca Mascitelli, Mark R. Goldstein

Erschienen in: Drugs & Aging | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

It is widely believed that the connection between cholesterol elevation and atherosclerotic plaques is clear and well established, with the consequent assumption that “atherosclerosis is a cholesterol problem”,[1] and that “[HMG-CoA reductase inhibitor] statin drugs are to atherosclerosis what penicillin was to infectious disease”.[2] However, controversy continues to surround the aetiology and pathogenesis of atherosclerosis, particularly with respect to cholesterol and lipids.[3] It has also been suggested that hypercholesterolaemia does not represent a causa sine qua non for the development of atherosclerosis, and that the beneficial effects of statins are overstated and do not resolve the cholesterol controversy.[4] …

Roberts WC. Atherosclerosis: its cause and its prevention. Am J Cardiol 2006; 98(11): 1550–5CrossRef

Roberts WC. The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol 1996; 78(3): 377–8PubMedCrossRef

Stehbens WE. Coronary heart disease, hypercholesterolemia and atherosclerosis: I. False premises. Exp Mol Pathol 2001; 70(2): 103–9PubMedCrossRef

Mascitelli L, Pezzetta F, Goldstein MR. Why the overstated beneficial effects of statins do not resolve the cholesterol controversy. QJM 2009; 102(6): 435–6PubMedCrossRef

Petretta M, Costanzo P, Perrone-Filardi P, et al. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol 2010; 138(1): 25–31PubMedCrossRef

Mangin D, Sweeney K, Heath I. Preventive health care in elderly people needs rethinking. BMJ 2007; 335(7614): 285–7PubMedCentralPubMedCrossRef

Shepherd J, Blauw GJ, Murphy MB, et al.; PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623–30PubMedCrossRef

Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchial Bayesian meta-analysis. J Am Coll Cardiol 2008; 51(1): 37–45PubMedCrossRef

Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? [published erratum appears in Diabetologia 2005; 48 (8): 1677]. Diabetologia 2005; 48(6): 1038–50PubMedCrossRef

10.

Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering: are they clinically relevant? Eur Heart J 2003; 24(3): 225–48PubMedCrossRef

11.

Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103(3): 357–62PubMedCrossRef

12.

Keech A, Colquhoun D, Best J, et al.; LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26(10): 2713–21PubMedCrossRef

13.

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195–207PubMedCrossRef

14.

Mascitelli L, Goldstein MR. Statins, cholesterol depletion and risk of incident diabetes. Int J Cardiol 2011; 152(2): 275–6PubMedCrossRef

15.

Lee JW, Brancati FL, Yeh HC. Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997–2008. Diabetes Care 2011; 34(2): 353–7PubMedCentralPubMedCrossRef

16.

Goldstein MR, Mascitelli L. Statin-induced diabetes: perhaps, it’s the tip of the iceberg. QJM 2011; 104(2): 174–8PubMedCrossRef

17.

Koh KK, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hyper-cholesterolemic patients. J Am Coll Cardiol 2010; 55(12): 1209–16PubMedCentralPubMedCrossRef

18.

Koh KK, Quon MJ, Han SH, et al. Simvastatin improves flow-mediated dilatation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008; 31(4): 776–82PubMedCentralPubMedCrossRef

19.

Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204(2): 483–90PubMedCentralPubMedCrossRef

20.

Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systemic review. Br J Cancer 2006; 94(9): 1221–5PubMedCentralPubMedCrossRef

21.

Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Letters 2001; 507(3): 357–61PubMedCrossRef

22.

Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49(8): 1881–92PubMedCrossRef

23.

Bickel PE. Lipid rafts and insulin signaling. Am J Physiol Endocrinol Metab 2002; 282(1): E1–E10PubMed

24.

Shepherd PR, Kahn BB. Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341(4): 248–57PubMedCrossRef

25.

Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001; 409(6821): 729–33PubMedCrossRef

26.

Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202(3): 654–62PubMedCrossRef

27.

Ortega AD, Sánchez-Aragó M, Giner-Sánchez D, et al. Glucose avidity of carcinomas. Cancer Lett 2009; 276(2): 125–35PubMedCrossRef

28.

Cooper R, Sarioğlu S, Sökmen S, et al. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003; 89(5): 870–6PubMedCentralPubMedCrossRef

29.

Xia F, Xie L, Mihic A, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic β-cells. Endocrinology 2008; 149(10): 5136–45PubMedCrossRef

30.

Ma T, Chang MH, Tien L, et al. The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs Aging 2012; 29(1): 45–51PubMedCrossRef

31.

Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011 Mar; 215(1): 1–8PubMedCrossRef

32.

Thompson R, O’Regan C, Morant S, et al. Measurement of baseline total cholesterol: new data from The Health Improvement Network (THIN) database. Prim Care Cardiovasc J 2008; 1(2): 107–11CrossRef

33.

Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78(4): 330–41PubMedCrossRef

34.

Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305(24): 2556–64PubMedCrossRef

35.

Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA 2005; 294(14): 1773–81PubMedCrossRef

36.

Cohen JD, Cziraky MJ, Cai Q, et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006 [published erratum appears in Am J Cardiol 2010; 106 (12): 1826]. Am J Cardiol 2010; 106(7): 969–75PubMedCrossRef

37.

Bouillon K, Singh-Manoux A, Jokela M, et al. Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study. Heart 2011; 97(11): 923–30PubMedCentralPubMedCrossRef

38.

Danaei G, Finucane MM, Lu Y, et al.; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378(9785): 31–40PubMedCrossRef

39.

Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+−year olds. Age Ageing 2010; 39(6): 674–80PubMedCentralPubMedCrossRef

40.

Goldstein MR, Mascitelli L, Pezzetta F. Statin therapy in the elderly: misconceptions. J Am Geriatr Soc 2008; 56(7): 1365PubMedCrossRef

Titel: Long-Standing Statin Therapy and the Risk of New-Onset Diabetes in the Elderly
Collateral Damage Caused by Preventive Medicine?
verfasst von: Dr Luca Mascitelli
Mark R. Goldstein
Publikationsdatum: 01.01.2012
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 1/2012
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/11598530-000000000-00000

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Long-Standing Statin Therapy and the Risk of New-Onset Diabetes in the Elderly

Collateral Damage Caused by Preventive Medicine?

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Antimicrobial Prescribing in Hospitalized Adults Stratified by Age

Health State Values for Use in the Economic Evaluation of Treatments for Alzheimer’s Disease

Potential Beneficial Effects of Low Molecular Weight Heparin on Cognitive Impairment in Elderly Patients on Haemodialysis

Spotlight on Eldecalcitol in Osteoporosis

Drugs in Clinical Development for Alzheimer’s Disease

Psychotropic Drug-Induced Falls in Older People

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin